Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology

Treating DME: From Injections to Observation

At a Glance

For diabetic macular edema causing vision loss, anti-VEGF medicines injected into the eye are usually the first treatment. People with excellent vision may be monitored instead, while steroid implants or laser are reserved for selected situations and require follow-up.

The standard treatment for Diabetic Macular Edema (DME) has been transformed by medications injected directly into the eye. These drugs dry out the swelling and protect your sight. While the idea of an eye injection can be daunting, these treatments are remarkably effective at preventing vision loss and often restore vision you may have already lost [1][2].

First-Line Treatment: Anti-VEGF Injections

For most people with center-involving DME causing vision loss, the first-line treatment is a class of drugs called anti-VEGF agents. These drugs block a protein (VEGF) that drives vessel leakage [3].

Commonly used anti-VEGF medications include:

  • Aflibercept (Eylea/Eylea HD)
  • Ranibizumab (Lucentis)
  • Bevacizumab (Avastin) — often used “off-label”
  • Faricimab (Vabysmo) — a newer drug targeting both VEGF and another protein called Ang-2 [4]

Protocol T Findings

A landmark study (Protocol T) compared aflibercept, ranibizumab, and bevacizumab [5].

  • If starting vision was 20/40 or better: All three standard drugs produced similar visual gains [6].
  • If starting vision was 20/50 or worse: Aflibercept resulted in greater average vision gains at one year compared to bevacizumab [5][7].
    Note: This study predates newer options like faricimab and high-dose aflibercept. Drug choice depends on response, safety, cost, access, and clinician judgment, not just a strict visual acuity rule.

Regimens and Intervals

Treatment often begins with an initial series of frequent injections (sometimes called a “loading phase”) to get the swelling under control [8][5]. Depending on the drug and your eye’s response, your doctor may then use a treat-and-extend protocol or customized intervals, gradually increasing the time between visits as long as the retina remains stable [9][10]. Schedules vary widely by agent, label, and clinician preference.

When Observation is an Option

If you have center-involving DME but your vision remains excellent (typically 20/25 or better), your doctor may suggest carefully monitored observation [11]. A major trial (Protocol V) showed that for selected patients, monitoring the eye and only starting injections if vision worsened was a safe approach [11]. This approach requires strict adherence to follow-up appointments and is not appropriate for everyone.

Second-Line Therapy: Corticosteroids

If anti-VEGF injections do not adequately dry the macula, or for patients with specific clinical profiles, doctors may consider intravitreal corticosteroids like the Dexamethasone implant (Ozurdex) or Fluocinolone implant (Iluvien) [12][13].
(Note: A recent heart attack or stroke warrants a risk-benefit discussion with your specialist before using anti-VEGF, but it does not make steroid implants automatically safe or indicated. Pregnancy also requires an individualized discussion with your eye and obstetric teams).

Steroids carry two significant risks that require close monitoring:

  1. Cataracts: Many patients with their natural lenses will eventually see an acceleration of cataracts after steroid treatment [14][15].
  2. Eye Pressure (IOP) Spikes: A significant portion of patients will experience an increase in eye pressure, which may require daily eye drops or, occasionally, surgery to prevent glaucoma [16][15].

What to Expect During an Injection

If you are receiving an eye injection, the process is quick. First, the team cleans your eye with an antiseptic solution (like iodine) to prevent infection. They will use numbing drops or a small anesthetic injection so you do not feel sharp pain. You will likely feel a brief sense of pressure. Afterward, it is completely normal to experience temporary blurry vision, see new floaters (often the medication itself), or notice a small red spot on the white of your eye (a surface hemorrhage) that will heal on its own. Because your eyes may be dilated and blurry, you should arrange for someone to drive you home.

The Role of Laser and Rare Risks

  • Macular Laser: While historically the primary treatment, laser is now mostly used as an “add-on” for persistent swelling or for DME that does not involve the center of the macula [17][18].
  • Serious Risks: Although rare, the most serious risks of any eye injection include endophthalmitis (a severe internal infection) and retinal detachment [19][20]. These occur infrequently, but any new pain, severe redness, increasing light sensitivity, or sudden vision loss in the days following an injection requires immediate, same-day medical attention.

Common questions in this guide

What is the usual first treatment for diabetic macular edema?
For most people whose DME involves the center of the macula and is reducing vision, anti-VEGF medicine injected into the eye is the usual first treatment. Common options include aflibercept, ranibizumab, bevacizumab, and faricimab, and the choice depends on response, safety, cost, access, and clinician judgment.
Can diabetic macular edema be watched instead of treated right away?
Sometimes. If center-involving DME is present but vision is still excellent, often 20/25 or better, close observation with regular visits may be reasonable, with injections started if vision worsens. This requires reliable follow-up and is not appropriate for everyone.
How often will I need DME eye injections?
Treatment often starts with several frequent injections, sometimes called a loading phase. If the swelling improves, your doctor may gradually lengthen the time between visits using a treat-and-extend or customized schedule; the interval depends on the medicine and your eye's response.
What happens if anti-VEGF injections do not control diabetic macular edema?
Your retina specialist may consider intravitreal corticosteroids, such as dexamethasone or fluocinolone implants, for selected patients. Steroids can speed cataract progression and raise eye pressure, so the lens and eye pressure need monitoring; laser may be used as an add-on for persistent or non-center-involving DME.
Which symptoms after an eye injection need urgent medical attention?
Temporary blurry vision, new floaters, or a small red spot on the white of the eye can occur after an injection. Any new pain, severe redness, increasing light sensitivity, or sudden vision loss requires same-day medical attention.

Get notified when new evidence is published on diabetic macular edema.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Türkiye: 48-Month Data, BOSPHORUS-DME Study Group Report No. 1.

    Özal E, Özkaya A, Arıcı M, et al.

    Turkish journal of ophthalmology 2026; (56(1)):31-40 doi:10.4274/tjo.galenos.2026.67863.

    PMID: 41705877
  2. 2

    Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.

    Bressler NM, Beaulieu WT, Glassman AR, et al.

    JAMA ophthalmology 2018; (136(3)):257-269 doi:10.1001/jamaophthalmol.2017.6565.

    PMID: 29392288
  3. 3

    The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When.

    Salvetat ML, Pellegrini F, Spadea L, et al.

    Journal of clinical medicine 2024; (13(5)) doi:10.3390/jcm13051327.

    PMID: 38592149
  4. 4

    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

    Wykoff CC, Abreu F, Adamis AP, et al.

    Lancet (London, England) 2022; (399(10326)):741-755 doi:10.1016/S0140-6736(22)00018-6.

    PMID: 35085503
  5. 5

    Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

    , Wells JA, Glassman AR, et al.

    The New England journal of medicine 2015; (372(13)):1193-203 doi:10.1056/NEJMoa1414264.

    PMID: 25692915
  6. 6

    Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

    Wells JA, Glassman AR, Ayala AR, et al.

    Ophthalmology 2016; (123(6)):1351-9.

    PMID: 26935357
  7. 7

    Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.

    Cai S, Bressler NM

    Current opinion in ophthalmology 2017; (28(6)):636-643 doi:10.1097/ICU.0000000000000424.

    PMID: 28837425
  8. 8

    Management of diabetic macular edema: experts' consensus in Taiwan.

    Chen JT, Chen LJ, Chen SN, et al.

    Japanese journal of ophthalmology 2020; (64(3)):235-242 doi:10.1007/s10384-020-00741-4.

    PMID: 32342244
  9. 9

    Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.

    Garweg JG, Štefanickova J, Hoyng C, et al.

    Advances in therapy 2022; (39(6)):2701-2716 doi:10.1007/s12325-022-02119-z.

    PMID: 35412227
  10. 10

    Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

    Wong TY, Haskova Z, Asik K, et al.

    Ophthalmology 2024; (131(6)):708-723 doi:10.1016/j.ophtha.2023.12.026.

    PMID: 38158159
  11. 11

    Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.

    Baker CW, Glassman AR, Beaulieu WT, et al.

    JAMA 2019; (321(19)):1880-1894 doi:10.1001/jama.2019.5790.

    PMID: 31037289
  12. 12

    Early Switch to Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema Poorly Responding to Anti-VEGF Therapy: A Narrative Review.

    Sacconi R, Scarinci F, Grassi MO, et al.

    Ophthalmology and therapy 2026; (15(3)):1033-1055 doi:10.1007/s40123-026-01324-1.

    PMID: 41722007
  13. 13

    Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema.

    Syed YY

    Drugs 2017; (77(5)):575-583 doi:10.1007/s40265-017-0722-4.

    PMID: 28283896
  14. 14

    Intravitreal steroids for macular edema in diabetes.

    Rittiphairoj T, Mir TA, Li T, Virgili G

    The Cochrane database of systematic reviews 2020; (11()):CD005656 doi:10.1002/14651858.CD005656.pub3.

    PMID: 33206392
  15. 15

    Fluocinolone acetonide for the treatment of diabetic macular edema.

    Veritti D, Sarao V, Diplotti L, et al.

    Expert opinion on pharmacotherapy 2017; (18(14)):1507-1516 doi:10.1080/14656566.2017.1363182.

    PMID: 28764565
  16. 16

    INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.

    Maturi RK, Pollack A, Uy HS, et al.

    Retina (Philadelphia, Pa.) 2016; (36(6)):1143-52 doi:10.1097/IAE.0000000000001004.

    PMID: 26871523
  17. 17

    [Diabetic maculopathy].

    Haritoglou C, Kernt M, Wolf A

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2015; (112(10)):871-83; quiz 884-6 doi:10.1007/s00347-015-0127-2.

    PMID: 26420681
  18. 18

    Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.

    Payne JF, Wykoff CC, Clark WL, et al.

    Ophthalmology 2017; (124(1)):74-81 doi:10.1016/j.ophtha.2016.09.021.

    PMID: 27836430
  19. 19

    Safety of 6000 intravitreal dexamethasone implants.

    Rajesh B, Zarranz-Ventura J, Fung AT, et al.

    The British journal of ophthalmology 2020; (104(1)):39-46 doi:10.1136/bjophthalmol-2019-313991.

    PMID: 31040132
  20. 20

    Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.

    Zehden JA, Mortensen XM, Reddy A, Zhang AY

    Current diabetes reports 2022; (22(10)):525-536 doi:10.1007/s11892-022-01491-y.

    PMID: 36053385

This page is for informational purposes only and does not constitute medical advice. Your retina specialist should tailor DME treatment and monitoring to your vision, OCT findings, eye pressure, and overall health.

Guide contents diabetic macular edema
Research & Literature
03 Decoding Your OCT Scan 05 Living with DME